The impact of Fc receptor like molecules (including FCRL1 and FCRL2) have been elucidated in CLL, which predicts the IGHV mutation status and clinical progression [43], and can act as potential immunotherapeutic targets [61, 62]. The gene discussed is FCRL2; the disease is B-cell chronic lymphocytic leukemia.